Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 960.76 Thousand AUD | 29.76% |
| 2023 | 1.22 Million AUD | -29.16% |
| 2022 | 1.73 Million AUD | -38.41% |
| 2021 | 2.81 Million AUD | -68.9% |
| 2020 | 9.05 Million AUD | 18.43% |
| 2019 | 7.64 Million AUD | 15.0% |
| 2018 | 6.64 Million AUD | 15.0% |
| 2017 | 5.77 Million AUD | 14.96% |
| 2016 | 5.02 Million AUD | 233.26% |
| 2015 | 1.5 Million AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 700 Thousand AUD | 191.2% |
| 2009 | 240.38 Thousand AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | 1.59 Million AUD | 29.76% |
| 2024 Q2 | 1.61 Million AUD | 0.0% |
| 2024 Q4 | 960.76 Thousand AUD | 0.0% |
| 2023 Q2 | 952.65 Thousand AUD | 0.0% |
| 2023 Q4 | 1.22 Million AUD | 0.0% |
| 2023 FY | 1.22 Million AUD | -29.16% |
| 2022 FY | 1.73 Million AUD | -38.41% |
| 2022 Q4 | 1.73 Million AUD | 0.0% |
| 2022 Q2 | 3.03 Million AUD | 0.0% |
| 2021 Q2 | 9.75 Million AUD | 0.0% |
| 2021 FY | 2.81 Million AUD | -68.9% |
| 2021 Q4 | 2.81 Million AUD | 0.0% |
| 2020 Q4 | 9.05 Million AUD | 0.0% |
| 2020 FY | 9.05 Million AUD | 18.43% |
| 2020 Q2 | 8.48 Million AUD | 0.0% |
| 2019 FY | 7.64 Million AUD | 15.0% |
| 2019 Q4 | 7.64 Million AUD | 0.0% |
| 2019 Q2 | 7.14 Million AUD | 0.0% |
| 2018 Q4 | 6.64 Million AUD | 0.0% |
| 2018 Q2 | 6.21 Million AUD | 0.0% |
| 2018 FY | 6.64 Million AUD | 15.0% |
| 2017 Q4 | 5.77 Million AUD | 3.4% |
| 2017 Q3 | 5.58 Million AUD | 3.48% |
| 2017 Q2 | 5.4 Million AUD | 0.0% |
| 2017 FY | 5.77 Million AUD | 14.96% |
| 2016 Q2 | 4.69 Million AUD | 0.0% |
| 2016 FY | 5.02 Million AUD | 233.26% |
| 2016 Q4 | 5.02 Million AUD | 0.0% |
| 2015 FY | 1.5 Million AUD | 0.0% |
| 2015 Q4 | 1.5 Million AUD | 0.0% |
| 2015 Q2 | 667.08 Thousand AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2010 FY | 700 Thousand AUD | 191.2% |
| 2009 FY | 240.38 Thousand AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -275.897% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 28.493% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 21.785% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.785% |
| GB Sciences, Inc. | 1.75 Million USD | 45.39% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | 79.183% |
| Zenith Capital Corp. | 10.22 Thousand USD | -9296.215% |
| Agentix Corp. | 50 Thousand USD | -1821.526% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 83.636% |
| Biomind Labs Inc. | 735.54 Thousand USD | -30.62% |
| ContraFect Corporation | 2.88 Million USD | 66.652% |
| CSL Limited | 12.18 Billion USD | 99.992% |
| CytoDyn Inc. | 30.07 Million USD | 96.806% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -167.094% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -52.483% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 97.891% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1.317% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -27.051% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 96.772% |
| SQZ Biotechnologies Company | 27.47 Million USD | 96.503% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -8.186% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.668% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 58.694% |
| Mesoblast Limited | 118.7 Million USD | 99.191% |
| Marizyme, Inc. | 18.71 Million USD | 94.867% |
| Genus plc | 233.1 Million USD | 99.588% |
| Pharming Group N.V. | 171.54 Million USD | 99.44% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -28.102% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 33.572% |
| IMV Inc. | 28.88 Million USD | 96.674% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 83.02% |
| MultiCell Technologies, Inc. | 202.58 USD | -474163.501% |
| ONE Bio Corp. | 19.71 Million USD | 95.127% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.329% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.097% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 68.252% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 92.608% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -578.898% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3635.616% |
| Alpha Cognition Inc. | 1.22 Million USD | 21.273% |
| Enzolytics Inc. | 996.33 Thousand USD | 3.571% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 95.196% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 86.416% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.77% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 76.692% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -139.086% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 59.93% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -319.015% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -546.308% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 67.214% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -609.118% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 35.724% |
| Q BioMed Inc. | 4.1 Million USD | 76.624% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 95.274% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.58% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 79.608% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 57.458% |
| HST Global, Inc. | 98.31 Thousand USD | -877.19% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -286.283% |
| Halberd Corporation | 150 Thousand USD | -540.509% |
| Resverlogix Corp. | 6.49 Million USD | 85.199% |
| Cell Source, Inc. | 9.25 Million USD | 89.618% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 64.531% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -378.906% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 56.327% |
| Kadimastem Ltd | 891.22 Thousand USD | -7.802% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -355.392% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -284.026% |
| LadRx Corporation | 33.6 Thousand USD | -2758.903% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -27.051% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -320.692% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 80.719% |
| Mobile Lads Corp. | 484.28 Thousand USD | -98.388% |
| International Stem Cell Corporation | 4.17 Million USD | 77.004% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | 50.09% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -173.063% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 87.714% |
| SYBLEU INC | 477.5 Thousand USD | -101.207% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -684.296% |
| Rebus Holdings, Inc. | 310 Thousand USD | -209.924% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 79.711% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1439.364% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 55.946% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 88.447% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 88.809% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 38.234% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -258.494% |
| Neutra Corp. | 54.15 Thousand USD | -1674.066% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 47.499% |
| PureTech Health plc | 25.51 Million USD | 96.234% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 21.521% |
| IXICO plc | 472.02 Thousand USD | -103.542% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 93.802% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.457% |
| CSL Limited | 12.18 Billion USD | 99.992% |
| Cellectis S.A. | 92.77 Million USD | 98.964% |